Opko Health

(NASDAQ) OPK

Current Price$1.20

Market Cap$906.11M

Since IPO (1995)-73%

5 Year-66%

1 Year-10%

1 Month-14%

Opko Health last closing stock price
Metric	Price	Date
Last close	USD 1.20	2026-07-15

Opko Health stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-14.89%	USD 1.41	2026-07-08
1 month	-14.29%	USD 1.40	2026-06-15
3 month	-0.83%	USD 1.21	2026-04-16
Year to date	-4.76%	USD 1.26	2025-12-31
1 year	-9.77%	USD 1.33	2025-07-15
3 year	-42.58%	USD 2.09	2023-07-14
5 year	-65.71%	USD 3.50	2021-07-16
Since inception	-73.33%	USD 4.50	1995-11-02

Opko Health Financials at a Glance

Market Cap

$906.11M

Revenue (TTM)

$581.12M

Net Income (TTM)

-$212.92M

EPS (TTM)

-$0.27

P/E Ratio

-4.38

Dividend

$0.00

Beta (Volatility)

1.25 (Average)

Dividend

$0.00

Beta (Volatility)

1.25 (Average)

Price

$1.20

Volume

3,723,423

Open

$1.20

Price

$1.20

Volume

3,723,423

Open

$1.20

Previous Close

$1.19

Daily Range

$1.18 - $1.22

52-Week Range

$0.98 - $1.61

Estimated Earnings Date

Jul 30, 2026

Dividend

$0.00

Beta (Volatility)

1.25 (Average)

Price

$1.20

Volume

3,723,423

Open

$1.20

Previous Close

$1.19

Daily Range

$1.18 - $1.22

52-Week Range

$0.98 - $1.61

Estimated Earnings Date

Jul 30, 2026

OPK News

Page 1

OPK: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Opko Health

OPKO helps doctors and patients by providing medical tests and specialty medicines. The company runs laboratories that check for diseases and develops treatments for kidney conditions. These services help people manage their health through better information and targeted drugs.

Health Tests and Kidney Care

Laboratory Services: Clinical and women's health testing provided through BioReference laboratories; accounts for 58% of revenue.
Kidney Disease Treatment: Rayaldee medicine used to treat hormone issues in adults with chronic kidney disease; part of the pharmaceutical segment.
Specialty Diagnostics: Prostate cancer testing using the proprietary 4Kscore blood test; included in laboratory service revenue.
Growth Hormones: NGENLA, a once-weekly injection for children with growth disturbances; revenue comes from royalties and intellectual property transfers.

Deals and Developments

Consummated the sale of certain oncology and clinical testing assets to Labcorp in September 2025.
Purchased ModeX Therapeutics to focus on multi-specific immune therapies for cancer and infectious diseases.
Collaborated with Pfizer to bring the growth hormone NGENLA to more than 50 markets worldwide.
Entered an agreement with NextPlat Corp in October 2023 to launch an online storefront in China.

International Reach and Innovation

The company maintains a global presence with pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. It uses specialized technology to develop longer-acting versions of therapeutic proteins that have already received regulatory approval.

Key Financial Data

Revenue was $124.2 million in Q1 2026, down 17.2% from $150 million in Q1 2025.
Net loss was $54.8 million in Q1 2026, which improved from a loss of $67.6 million in Q1 2025.
Operating cash flow was negative $19.3 million in Q1 2026, narrowing from negative $34.6 million in Q1 2025.
Gross profit was $26.8 million in Q1 2026, up 17.7% from $22.8 million in Q1 2025.

Bottom Line

OPKO has transitioned from a diagnostics-heavy firm into a diversified healthcare entity with international pharmaceutical operations. Its shift toward high-specialty testing and partnership-driven drug commercialization defines its current structure.

AI Generated • May 3, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

2,275

CEO

Phillip Frost, MD

Website

www.opko.com

Headquarters

Miami, FL 33137, US

OPK Financials

Key Financial Metrics (TTM)

Gross Margin

22.73%

Operating Margin

-34.90%

Net Income Margin

-36.64%

Return on Equity

-16.78%

Return on Capital

-12.87%

Return on Assets

-11.47%

Earnings Yield

-22.83%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$906.11M

Shares Outstanding

755.09M

Volume

3.72M

Avg. Volume

2.78M

Financials (TTM)

Gross Profit

$132.08M

Operating Income

-$202.84M

EBITDA

-$34.69M

Operating Cash Flow

-$163.30M

Capital Expenditure

-$10.92M

Free Cash Flow

-$174.22M

Cash & ST Invst.

$341.88M

Total Debt

$396.93M

Opko Health Performance Analysis

Opko Health annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 1,004,196,000	-43.4%
2023	2023-12-31	USD 863,495,000	-14.0%
2024	2024-12-31	USD 713,142,000	-17.4%
2025	2025-12-31	USD 606,879,000	-14.9%

Opko Health sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	4.6%
Q3	2025-09-30	-3.3%
Q4	2025-12-31	-2.1%
Q1	2026-03-31	-16.3%

Opko Health annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.46	882.2%
2023	2023-12-31	USD -0.25	-45.0%
2024	2024-12-31	USD -0.08	-69.5%
2025	2025-12-31	USD -0.30	291.7%

Opko Health sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-90.0%
Q3	2025-09-30	114.6%
Q4	2025-12-31	-247.3%
Q1	2026-03-31	-77.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$124.20M

-17.2%

Gross Profit

$26.79M

+17.7%

Gross Margin

21.57%

N/A

Market Cap

$906.11M

N/A

Market Cap/Employee

$398.29K

N/A

Employees

2,275

N/A

Net Income

-$54.85M

+18.9%

EBITDA

-$27.82M

+19.2%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$341.88M

-21.6%

Total Debt

$396.93M

-19.5%

Accounts Receivable

$107.62M

-16.4%

Inventory

$64.40M

+0.6%

Long Term Debt

$374.67M

+1.8%

Short Term Debt

$22.26M

-82.2%

Return on Assets

-11.47%

N/A

Return on Invested Capital

-11.87%

N/A

Free Cash Flow

-$21.14M

+44.0%

Operating Cash Flow

-$19.31M

+44.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

SANASana Biotechnology, Inc.

SANASana Biotechnology, Inc.$3.17-10.70%

PCRXPacira BioSciences, Inc.

PCRXPacira BioSciences, Inc.$25.60+1.07%

OCSOculis Holding AG

OCSOculis Holding AG$12.61-3.89%

XNCRXencor, Inc.

XNCRXencor, Inc.$14.95-0.20%

TNDMTandem Diabetes Care, Inc.

TNDMTandem Diabetes Care, Inc.$16.29+6.61%

CTEVClaritev Corporation

CTEVClaritev Corporation$30.76+4.48%

NKTRNektar Therapeutics

NKTRNektar Therapeutics$67.05-1.83%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

AALAmerican Airlines Group

AALAmerican Airlines Group$15.60-0.00%

ATAIAtaiBeckley

ATAIAtaiBeckley$7.15+0.33%

NOKNokia

NOKNokia$10.38-0.08%

SOFISoFi Technologies

SOFISoFi Technologies$17.32-0.03%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$70.74-0.05%

AAPLApple

AAPLApple$333.26+0.02%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$131.11-0.03%

Questions About OPK

What is the current price of Opko Health?

Opko Health is trading at $1.19 per share.

What is the 52-week range for Opko Health?

Over the past 52 weeks, Opko Health has traded between $0.98 and $1.61.

How much debt does Opko Health have?

As of the most recent reporting period, Opko Health reported total debt of $396.93M.

How much cash does Opko Health have on hand?

Opko Health reported $341.88M in cash and cash equivalents in its most recent financial results.

What is Opko Health’s dividend yield?

Opko Health does not currently have a dividend yield.

Opko Health

Opko Health Financials at a Glance

OPK News

Opko Health (OPK) Q2 Revenue Falls 14%

Why Shares of Opko Health Jumped on Thursday

Why OPKO Health Shares Jumped on Wednesday

Why Opko Health Stock Was a Surprise Winner This Week

Why Opko Health Stock Is Jumping Today

Why Opko Health Stock Dipped on Friday

Why Opko Health Stock Is Crashing This Week

Why Opko Health Stock Is Off 23% Today

OPK: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Opko Health

Health Tests and Kidney Care

Deals and Developments

International Reach and Innovation

Key Financial Data

Bottom Line

OPK Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Opko Health Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About OPK

What is the current price of Opko Health?

What is the 52-week range for Opko Health?

How much debt does Opko Health have?

How much cash does Opko Health have on hand?

What is Opko Health’s dividend yield?

Premium Investing Services